Login to Your Account

ORIC's $53M series B shines spotlight on cancer drug resistance

By Jennifer Boggs
Managing Editor

Wednesday, December 2, 2015

A group of top-tier investors came together in a $53 million series B round for 2014 start-up ORIC Pharmaceuticals Inc., a company whose goal can be summed up neatly in its acronym: overcoming resistance in cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription